1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Mabwell (Shanghai) Bioscience Co., Ltd. Class A

Mabwell (Shanghai) Bioscience Co., Ltd. Class A

19.20
HKD
+0.15
(+0.79%)
-2.57EPS
14.42BMarket Cap
Oct 28Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.01
0.09
0.07
0.01
0.04
0.05
0.23
0.36
1.2
0.89
Basic EPS, GAAP
-0.25
-0.54
-2.24
-1.63
-1.86
-1.76
-1.91
-1.89
-1.76
-2.21
Free Cash Flow per Basic Share
-0.64
-0.92
-1.3
-1.64
-1.54
-2.33
-2.32
-2.32
-0.81
- -
Dividend per Share
- -
- -
- -
- -
- -
0.02
0.06
0.12
0.14
0.16
Book Value per Share
0.2
-0.34
1.82
3.54
2.44
6.36
4.67
2.84
0.63
1.41
Tangible Book Value per Share
-0.57
-1.11
1.09
2.8
1.72
5.85
4.2
2.35
0.15
0.99
Basic Weighted Avg Shares
415
415
415
394
415
542
552
554
552
521
Sales/Revenue/Turnover
5
37
29
5
16
28
128
200
663
466
Operating Margin (%)
-2,327.08
-489.28
-3,155.73
-12,386
-4,781.07
-3,575.42
-837.14
-498.18
-128.49
-218.52
Depreciation Expense
16
22
43
56
80
89
104
145
218
- -
Net Income, GAAP
-103
-225
-928
-643
-770
-955
-1,053
-1,044
-969
-1,153
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-2,231.9
-602.59
-3,153.34
-12,118.54
-4,742.85
-3,445
-824.05
-522.53
-146.31
-247.58
Working Capital
-320
-795
-158
489
-26
2,333
1,231
163
-220
573
LT Debt
- -
- -
- -
99
305
653
1,055
1,149
1,455
1,631
Total Equity
83
-132
757
1,470
1,009
3,511
2,573
1,556
533
1,054
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-57.7
-62.03
-42.21
-34.54
-50.28
-101.06
-107.22

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,465
1,655
1,671
LT Borrowings
1,341
1,455
1,554
LT Finance Leases
114
79
77
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
553
553
618
Market Capitalization
- -
- -
12,477

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,039
2,113
2,876
Cash, Cash Equivalents & STI
1,528
1,489
2,292
Accounts Receivable, Net
100
128
128
Inventories
188
198
198
Total Current Liabilities
2,259
2,412
2,303
Payables & Accruals
- -
- -
- -
ST Debt
1,465
1,655
1,671
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
16.93%
-65.74%
Free Cash Flow
- -
6.65%
-65.18%
Net Income, GAAP
- -
9.23%
-7.14%
Sales/Revenue/Turnover
- -
185.17%
231.62%
Total Cash Common Dividend
- -
362.32%
18.56%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
68
48
26
59
200
2025
45
56
- -
97
663
2026
128
185
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.37
-0.43
-0.45
-0.63
-1.89
2025
-0.53
-0.47
- -
-0.67
-1.76
2026
-0.44
-0.65
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.03
0.03
0.04
0.12
2025
0.04
0.03
- -
0.04
0.14
2026
0.04
0.05
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Da Tao Liu
Full Time Employees
1,325
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building 2 Room 105, No. 230 Cailun RoadChina (Shanghai) Pilot Free Trade Zone Shanghai, 201210China Shanghai SH China 201210
IPO Date
Jan 18, 2022
Website
mabwell.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) is a China-based innovation-driven biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of biologic drugs across oncology, immunology, ophthalmology, bone disorders, hematology, infectious diseases, metabolism, and cardiovascular disease; the company offers approved products including JUNMAIKANG (adalimumab biosimilar for autoimmune diseases such as rheumatoid arthritis), MAILISHU and MAIWEIJIAN (denosumab biosimilars for postmenopausal osteoporosis and giant cell tumor of bone), MAILISHENG (albipagrastim alfa, a novel long-acting G-CSF using albumin fusion technology for chemotherapy-induced neutropenia), alongside a robust pipeline of over 30 candidates such as anti-ST2 antibody 9MW1911 (phase II for COPD and fibrosis), anti-IL-11 antibody 9MW3811 (phase II for pathological scarring), B7-H3 ADC 7MW3711 (phase I/II oncology), CDH17 ADC 7MW4911 (IND cleared), anti-VEGF 9MW0813 (NDA submitted for wet AMD), and 9MW3011 (phase II hematology for iron overload). Founded in 2017 and headquartered at Building 3, No. 576 Libing Road, Pudong New Area, Shanghai, China, Mabwell operates manufacturing bases in Taizhou and Shanghai (GMP-compliant, EU QP audited), R&D sites in Shanghai, Beijing, Nanjing, and San Diego, US, and serves domestic and international markets. Recent developments include the September 2025 strategic collaboration with Insilico Medicine and ChemExpress to develop a novel ADC compound library; formation of Kalexo Bio with Aditum Bio for siRNA therapy 2MW7141 in cardiovascular disease; licensing agreements for 9MW3811 with Calico, albipagrastim alfa with Qilu Pharmaceutical, and 9MW3011 with Disc Medicine (up to $412.5 million milestones); NMPA approvals for phase II trials of 9MW3811 and IND clearance for 7MW4911; NDA acceptance for 9MW0813; first-patient dosing in US phase II for 9MW3011; and positive phase IIa data for 9MW1911 reducing severe COPD exacerbations by over 40%.